Our proprietary personalized biologics approach

Targeting the underlying cause of diseases affecting the skin and connective tissue to bring relief to patients and their families

Learn More

Our focus on the patient drives everything we do and as a result, our path forward is clear: to develop game-changing cell and gene therapies for localized treatment of the underlying cause of debilitating diseases.

— David Pernock, Chairman and Chief Executive Officer

Our robust development pipeline of personalized biologics for localized treatment

Applying the unique characteristics of autologous fibroblasts to cell and gene therapies

FCX-007 offers the potential to address the underlying cause of RDEB by providing high levels of functional Type VII collagen locally to the affected areas.

Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

FCX-013 offers the potential to address the underlying cause of linear scleroderma by regulating collagen accumulation at the site of the localized disease.

Gene Therapy for Linear Scleroderma

Goal is to deliver a protein therapy locally to the joint providing sustained efficacy while avoiding key side effects typically associated with systemic therapy.